October 2, 2020 Synthetic Biologics Provides Update on Investigator-Sponsored Phase 2b Clinical Study of SYN-010 in IBS-C Patients
August 6, 2020 Synthetic Biologics Reports 2020 Second Quarter Operational Highlights and Financial Results
July 30, 2020 Synthetic Biologics Announces FDA Clearance of Investigational New Drug Application for SYN-020 Intestinal Alkaline Phosphatase (IAP)
July 29, 2020 Synthetic Biologics to Report 2020 Second Quarter Operational Highlights and Financial Results on August 6, 2020
June 30, 2020 Synthetic Biologics Announces Submission of IND Application to U.S. FDA for SYN-020 Intestinal Alkaline Phosphatase
May 27, 2020 Synthetic Biologics Enters into Exclusive Option to License Intellectual Property for Use of SYN-020 to Treat and Prevent Age-Related Metabolic and Inflammatory Diseases
May 5, 2020 Synthetic Biologics Reports 2020 First Quarter Operational Highlights and Financial Results
April 28, 2020 Synthetic Biologics to Report 2020 First Quarter Operational Highlights and Financial Results on May 5, 2020
February 20, 2020 Synthetic Biologics Reports 2019 Year End Operational Highlights and Financial Results
February 13, 2020 Synthetic Biologics to Report 2019 Year End Operational Highlights and Financial Results on February 20, 2020
